Literature DB >> 26561487

Multiple Bacteriophage Selection Strategies for Improved Affinity of a Peptide Targeting ERBB2.

Benjamin M Larimer1, Jeanne M Quinn2, Kevin Kramer2, Andrey Komissarov3, Susan L Deutscher1.   

Abstract

Due to the heterogeneity of ERBB2-expression between tumors and over the course of treatment, a non-invasive molecular imaging agent is needed to accurately detect overall ERBB2 status. Peptides are a highly advantageous platform for molecular imaging, since they have excellent tumor penetration and rapid pharmacokinetics. One limitation of peptides however, is their traditionally low target affinity, and consequently, tumor uptake. The peptide KCCYSL was previously selected from a bacteriophage (phage) display library to bind ERBB2 and did so with moderate affinity of 295 nM. In order to enhance tumor uptake and clinical utility of the peptide, a novel phage microlibrary was created by flanking the parent sequence with random amino acids, followed by reselection using parallel strategies for high affinity and specific ERBB2 binding in an attempt to affinity maturate the peptide. One limitation of traditional phage display selections is difficulty in releasing the highest affinity phages from the target by incubation of acidic buffer. In an attempt to recover high affinity second-generation peptides from the ERBB2 microlibrary, two elution strategies, sonication and target elution, were undertaken. Sonication resulted in an approximately 50-fold enhancement in recovered phage per round of selection in comparison to target elution. Despite the differences in elution efficiency, the affinities of phage-displayed peptides selected from either strategy were relatively similar. Although both selections yielded peptides with significantly improved affinity in comparison to KCCYSL, the improvements were modest, most likely because the parental peptide binding cannot be improved by additional amino acids.

Entities:  

Keywords:  Affinity Maturation; ERBB2; Peptides; Phage Display

Year:  2015        PMID: 26561487      PMCID: PMC4637174          DOI: 10.1007/s10989-015-9467-7

Source DB:  PubMed          Journal:  Int J Pept Res Ther        ISSN: 1573-3149            Impact factor:   1.931


  24 in total

1.  Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library.

Authors:  E Koivunen; D A Gay; E Ruoslahti
Journal:  J Biol Chem       Date:  1993-09-25       Impact factor: 5.157

2.  Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

Authors:  J Baselga; D Tripathy; J Mendelsohn; S Baughman; C C Benz; L Dantis; N T Sklarin; A D Seidman; C A Hudis; J Moore; P P Rosen; T Twaddell; I C Henderson; L Norton
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

Review 3.  A ticket to ride: peptide radiopharmaceuticals.

Authors:  A J Fischman; J W Babich; H W Strauss
Journal:  J Nucl Med       Date:  1993-12       Impact factor: 10.057

4.  Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab.

Authors:  Hyun-Soo Cho; Karen Mason; Kasra X Ramyar; Ann Marie Stanley; Sandra B Gabelli; Dan W Denney; Daniel J Leahy
Journal:  Nature       Date:  2003-02-13       Impact factor: 49.962

5.  Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.

Authors:  José Baselga; Karen A Gelmon; Shailendra Verma; Andrew Wardley; Pierfranco Conte; David Miles; Giulia Bianchi; Javier Cortes; Virginia A McNally; Graham A Ross; Pierre Fumoleau; Luca Gianni
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

6.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells.

Authors:  P P Di Fiore; J H Pierce; M H Kraus; O Segatto; C R King; S A Aaronson
Journal:  Science       Date:  1987-07-10       Impact factor: 47.728

7.  111In-labeled galectin-3-targeting peptide as a SPECT agent for imaging breast tumors.

Authors:  Senthil R Kumar; Susan L Deutscher
Journal:  J Nucl Med       Date:  2008-04-15       Impact factor: 10.057

8.  Development of Herceptin resistance in breast cancer cells.

Authors:  Timothy Kute; Christopher M Lack; Mark Willingham; Bimjhana Bishwokama; Holly Williams; Kathy Barrett; Tanita Mitchell; James P Vaughn
Journal:  Cytometry A       Date:  2004-02       Impact factor: 4.355

9.  Selection of phage antibodies by binding affinity. Mimicking affinity maturation.

Authors:  R E Hawkins; S J Russell; G Winter
Journal:  J Mol Biol       Date:  1992-08-05       Impact factor: 5.469

10.  Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma.

Authors:  Kimberly A Kelly; Nabeel Bardeesy; Rajesh Anbazhagan; Sushma Gurumurthy; Justin Berger; Herlen Alencar; Ronald A Depinho; Umar Mahmood; Ralph Weissleder
Journal:  PLoS Med       Date:  2008-04-15       Impact factor: 11.069

View more
  1 in total

1.  Structure-Activity Relationship of HER2 Receptor Targeting Peptide and Its Derivatives in Targeted Tumor Therapy.

Authors:  Beáta Biri-Kovács; Afrodité Adorján; Ildikó Szabó; Bálint Szeder; Szilvia Bősze; Gábor Mező
Journal:  Biomolecules       Date:  2020-01-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.